Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025
Apyx Medical (NASDAQ: APYX), developer of the proprietary Renuvion helium plasma and radiofrequency technology, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results release for March 13, 2025, before market opening.
The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (877-407-9039 for domestic, 201-689-8470 for international) using access code 13751519, or through the company's webcast link and Investor Relations website section.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. The company's products are supported by over 90 clinical documents and provide controlled heat tissue treatment.
Apyx Medical (NASDAQ: APYX), sviluppatore della tecnologia proprietaria Renuvion a plasma di elio e radiofrequenza, ha programmato la pubblicazione dei risultati finanziari del Quarto Trimestre e dell'Anno Fiscale 2024 per il 13 marzo 2025, prima dell'apertura del mercato.
L'azienda ospiterà una conferenza telefonica alle 8:30 ora orientale dello stesso giorno, con una discussione da parte della direzione e una sessione di domande e risposte. Le parti interessate possono partecipare telefonicamente (877-407-9039 per le chiamate nazionali, 201-689-8470 per quelle internazionali) utilizzando il codice di accesso 13751519, oppure attraverso il link per il webcast dell'azienda e la sezione del sito web delle Relazioni con gli Investitori.
Apyx Medical è specializzata nella tecnologia energetica avanzata, in particolare nella sua tecnologia Helium Plasma Platform, commercializzata come Renuvion nella chirurgia estetica e J-Plasma nei mercati chirurgici ospedalieri. I prodotti dell'azienda sono supportati da oltre 90 documenti clinici e offrono un trattamento controllato del tessuto mediante calore.
Apyx Medical (NASDAQ: APYX), desarrollador de la tecnología propietaria Renuvion de plasma de helio y radiofrecuencia, ha programado la publicación de sus resultados financieros del Cuarto Trimestre y Año Fiscal 2024 para el 13 de marzo de 2025, antes de la apertura del mercado.
La compañía llevará a cabo una conferencia telefónica a las 8:30 a.m. hora del Este el mismo día, que contará con una discusión de la dirección y una sesión de preguntas y respuestas. Las partes interesadas pueden unirse por teléfono (877-407-9039 para llamadas nacionales, 201-689-8470 para internacionales) utilizando el código de acceso 13751519, o a través del enlace de webcast de la compañía y la sección de Relaciones con Inversores en su sitio web.
Apyx Medical se especializa en tecnología de energía avanzada, particularmente su Tecnología de Plataforma de Plasma de Helio, comercializada como Renuvion en cirugía estética y J-Plasma en mercados quirúrgicos hospitalarios. Los productos de la empresa están respaldados por más de 90 documentos clínicos y ofrecen un tratamiento controlado del tejido mediante calor.
Apyx Medical (NASDAQ: APYX)는 독점 헬륨 플라즈마 및 라디오 주파수 기술인 Renuvion의 개발사로, 2024 회계 연도 및 4분기 재무 결과 발표를 2025년 3월 13일 시장 개장 전에 예정하고 있습니다.
회사는 같은 날 동부 표준시 기준 오전 8시 30분에 경영진의 토론과 질의응답 세션이 포함된 컨퍼런스 콜을 진행합니다. 관심 있는 분들은 전화(국내 877-407-9039, 국제 201-689-8470)를 통해 액세스 코드 13751519를 사용하여 참여하거나, 회사의 웹캐스트 링크 및 투자자 관계 웹사이트 섹션을 통해 참여할 수 있습니다.
Apyx Medical은 첨단 에너지 기술, 특히 헬륨 플라즈마 플랫폼 기술을 전문으로 하며, 이는 미용 수술에서 Renuvion으로, 병원 수술 시장에서 J-Plasma으로 판매됩니다. 회사의 제품은 90개 이상의 임상 문서에 의해 지원되며, 조절된 열 조직 치료를 제공합니다.
Apyx Medical (NASDAQ: APYX), développeur de la technologie propriétaire Renuvion à plasma d'hélium et radiofréquence, a prévu la publication de ses résultats financiers pour le quatrième trimestre et l'exercice 2024 pour le 13 mars 2025, avant l'ouverture du marché.
L'entreprise organisera une conférence téléphonique à 8h30, heure de l'Est, le même jour, comprenant une discussion de la direction et une session de questions-réponses. Les parties intéressées peuvent participer par téléphone (877-407-9039 pour les appels nationaux, 201-689-8470 pour les appels internationaux) en utilisant le code d'accès 13751519, ou via le lien de webcast de l'entreprise et la section Relations Investisseurs de son site web.
Apyx Medical est spécialisée dans la technologie énergétique avancée, en particulier sa technologie de plateforme à plasma d'hélium, commercialisée sous le nom de Renuvion en chirurgie esthétique et J-Plasma sur les marchés chirurgicaux hospitaliers. Les produits de l'entreprise sont soutenus par plus de 90 documents cliniques et offrent un traitement contrôlé des tissus par chaleur.
Apyx Medical (NASDAQ: APYX), Entwickler der proprietären Renuvion Helium-Plasma- und Radiofrequenztechnologie, hat die Veröffentlichung seiner finanziellen Ergebnisse für das 4. Quartal und das Geschäftsjahr 2024 für den 13. März 2025 vor der Markteröffnung angesetzt.
Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz veranstalten, die eine Diskussion des Managements und eine Frage-Antwort-Runde umfasst. Interessierte können telefonisch teilnehmen (877-407-9039 für nationale Anrufe, 201-689-8470 für internationale Anrufe) und den Zugangscode 13751519 verwenden oder über den Webcast-Link des Unternehmens und den Bereich für Investorenbeziehungen auf der Website teilnehmen.
Apyx Medical ist auf fortschrittliche Energietechnologie spezialisiert, insbesondere auf seine Helium-Plasma-Plattformtechnologie, die als Renuvion in der kosmetischen Chirurgie und als J-Plasma in den chirurgischen Krankenhausmärkten vermarktet wird. Die Produkte des Unternehmens werden von über 90 klinischen Dokumenten unterstützt und bieten eine kontrollierte Gewebebehandlung durch Wärme.
- Technology supported by extensive clinical evidence (90+ documents)
- Dual market presence in both cosmetic and hospital surgical sectors
- None.
CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th.
Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth quarter and fiscal year 2024, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13751519. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will be archived for future reference.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
FAQ
When will Apyx Medical (APYX) release its Q4 and FY 2024 earnings?
How can investors join APYX's Q4 2024 earnings call?
What are the main products of Apyx Medical (APYX)?
How many clinical documents support Apyx Medical's Renuvion and J-Plasma technologies?
